Aquestive Therapeutics (AQST) SVP gets stock, sells shares for taxes
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Aquestive Therapeutics SVP Melina Cioffi reported a mix of stock grants and tax-related sales. She received 100,000 shares of restricted common stock at no cost and a grant of options for 75,000 shares at a $4.29 exercise price, both vesting over three annual installments of 25%, 25%, and 50%.
On a separate date, she sold 25,311 common shares at a weighted average price of $4.173 per share to cover tax withholding tied to restricted stock unit vesting, a transaction mandated by the company’s equity plans rather than a discretionary trade. After these transactions, she directly holds 274,867 common shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 25,311 shares ($105,623)
Net Sell
3 txns
Insider
Cioffi Melina
Role
SVP, Regulatory Affairs
Sold
25,311 shs ($106K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 25,311 | $4.173 | $106K |
| Grant/Award | Non-Qualified Stock Option (right to buy) | 75,000 | $4.29 | $322K |
| Grant/Award | Common Stock | 100,000 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 274,867 shares (Direct);
Non-Qualified Stock Option (right to buy) — 75,000 shares (Direct)
Footnotes (1)
- The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. This transaction was executed in multiple trades at prices ranging from $4.17 to $4.32. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
FAQ
What insider transactions did Aquestive Therapeutics (AQST) SVP Melina Cioffi report?
Melina Cioffi reported receiving 100,000 restricted common shares and options for 75,000 shares, both vesting over three installments, plus selling 25,311 shares. The sale covered tax withholding from restricted stock unit vesting under company equity plan rules.
What new equity awards did Aquestive Therapeutics (AQST) grant to SVP Melina Cioffi?
She received 100,000 shares of restricted common stock and non-qualified stock options for 75,000 shares with a $4.29 exercise price. Both awards vest in three annual installments of 25%, 25%, and 50%, aligning compensation with longer-term company performance.
What are the vesting terms of the new Aquestive Therapeutics (AQST) equity awards?
Both the 100,000 restricted shares and 75,000 stock options vest in three annual installments, with 25% on the first installment date, 25% on the second, and 50% on the third. This staggered schedule encourages multi-year retention and performance alignment.
Are the Aquestive Therapeutics (AQST) insider sales discretionary trades?
The 25,311-share sale is described as a mandated sell-to-cover transaction to pay tax withholding on restricted stock unit vesting. According to the footnotes, these sales follow the company’s equity plan requirements and do not represent discretionary trading decisions by the executive.